TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29169314

Group type: EXPERIMENTAL
Intervention: Wideband amplification
Number of subjects: 73

Group type: COMPARATOR
Intervention: Digital Noise Reduction (DNR)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Normal hearing
Number of subjects: 73

Group type: COMPARATOR
Intervention: DNR
Number of subjects: 73
Study: 26156737

Group type: EXPERIMENTAL
Intervention: 50 μg vitamin D₃/d
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: 25 μg vitamin D₃/d
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: 10 μg vitamin D₃/d
Number of subjects: 226
Study: 23816038

Group type: EXPERIMENTAL
Intervention: Nurse telephone intervention providing monthly self-management support and quarterly medication management facilitation
Number of subjects: 359

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 359
Study: 20103547

Group type: EXPERIMENTAL
Intervention: Group care
Number of subjects: 815

Group type: COMPARATOR
Intervention: Individual care (Control)
Number of subjects: 815
Study: 18431475

Group type: EXPERIMENTAL
Intervention: Video Doctor counseling
Number of subjects: 476
Study: 16385521

Group type: EXPERIMENTAL
Intervention: infliximab + MTX
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo + MTX
Number of subjects: 24
Study: 12741142

Group type: EXPERIMENTAL
Intervention: Enzymatic antioxidant system activity in larynx cancer patients
Number of subjects: 28
Study: 10779419

Group type: EXPERIMENTAL
Intervention: BFM treatment with cranial irradiation
Number of subjects: 5006

Group type: COMPARATOR
Intervention: BFM treatment without cranial irradiation
Number of subjects: 5006
Study: 8865468

Group type: EXPERIMENTAL
Intervention: Lexipafant
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 1738794

Group type: COMPARATOR
Intervention: Deprivation plus no nicotine gum (n = 10)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Deprivation plus 0 mg nicotine gum (n = 20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Deprivation plus 2 mg nicotine gum (n = 20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Deprivation plus 4 mg nicotine gum (n = 20)
Number of subjects: 60
Study: 6627992

Group type: EXPERIMENTAL
Intervention: Coal tar gel (psoriGel) treatment for five days, followed by vegetable oil soaking on the sixth day and no treatment on the seventh day.
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Tar shampoo (Ionil T) after initial treatment.
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Nontar shampoo after initial treatment.
Number of subjects: 112
Study: 31922359

Group type: EXPERIMENTAL
Intervention: Hybrid revascularization
Number of subjects: 60

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 60
Study: 29432913

Group type: EXPERIMENTAL
Intervention: Fluconazole (100 mg per day for consecutive weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26721330

Group type: EXPERIMENTAL
Intervention: High-dose influenza vaccine (HD)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standard-dose influenza vaccine (SD)
Number of subjects: 105
Study: 24267397

Group type: EXPERIMENTAL
Intervention: Fractional bipolar RF
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fractional erbium-doped glass
Number of subjects: 20
Study: 23250592

Group type: EXPERIMENTAL
Intervention: Ozone therapy along with standard medications
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard medications
Number of subjects: 48
Study: 20054282

Group type: EXPERIMENTAL
Intervention: Full solid diet
Number of subjects: 210

Group type: COMPARATOR
Intervention: Clear liquid diet
Number of subjects: 210

Group type: COMPARATOR
Intervention: Soft diet
Number of subjects: 210
Study: 18724186

Group type: EXPERIMENTAL
Intervention: Eban HIV/STD Risk Reduction Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health Promotion Intervention (Control)
Number of subjects: 0
Study: 15963199

Group type: EXPERIMENTAL
Intervention: Salmeterol 25 microg/fluticasone propionate 125 microg (two puffs, twice daily) via HFA-MDI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salmeterol 50 microg/fluticasone propionate 250 microg (one puff, twice daily) via Diskus inhaler
Number of subjects: 0
Study: 12621133

Group type: EXPERIMENTAL
Intervention: 81 mg of aspirin daily
Number of subjects: 1121

Group type: EXPERIMENTAL
Intervention: 325 mg of aspirin daily
Number of subjects: 1121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1121
Study: 12110626

Group type: EXPERIMENTAL
Intervention: Multidrug treatment (MDT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (healthy individuals)
Number of subjects: 100
Study: 10674680

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 121
Study: 7784531

Group type: EXPERIMENTAL
Intervention: Complex finger movements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Foveally presented precue with varying intervals (0, 100, 300, or 1,400 ms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonlateralized, response-locked negativity
Number of subjects: 0
Study: 2207888

Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 7437209

Group type: EXPERIMENTAL
Intervention: Buprenorphine (i.m. administration)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Buprenorphine (i.v. administration)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Postoperative analgesic requirement (women)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Postoperative analgesic requirement (men)
Number of subjects: 20
Study: 30860682

Group type: EXPERIMENTAL
Intervention: LaVita® supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27825694

Group type: EXPERIMENTAL
Intervention: Shared decision-making (decision aid)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 204
Study: 25855342

Group type: EXPERIMENTAL
Intervention: Luseogliflozin 0.5 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Luseogliflozin 1 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Luseogliflozin 2.5 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Luseogliflozin 5 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Luseogliflozin (all doses)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 23494688

Group type: EXPERIMENTAL
Intervention: Screening and monitoring program for frail elderly patients based on routine care information in general practice
Number of subjects: 3008

Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention program by trained nurses for frail elderly patients in general practice
Number of subjects: 3008

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 3008

Group type: EXPERIMENTAL
Intervention: Screening and monitoring program
Number of subjects: 3008

Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention program
Number of subjects: 3008
Study: 21372706

Group type: EXPERIMENTAL
Intervention: Sliced orange intervention (OI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Deep breathing (control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Orange aromatherapy intervention (OAI)
Number of subjects: 60
Study: 19665366

Group type: EXPERIMENTAL
Intervention: Heated intravenous fluids (heated in a cabinet set at 45 degrees C)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Heated intravenous fluids (via Hotline fluid warmer)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Room temperature intravenous fluids
Number of subjects: 75
Study: 17038409

Group type: COMPARATOR
Intervention: 100 ml of contrast material (300 mg I ml(‐1)) only (Group A)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 100 ml of contrast material pushed with 50 ml of saline solution (Group B)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 85 ml of contrast material pushed with 50 ml of saline solution (Group C)
Number of subjects: 52
Study: 15104829

Group type: EXPERIMENTAL
Intervention: LAVH type ID (laparoscopic‐assisted abdominal colpotomy)
Number of subjects: 541

Group type: COMPARATOR
Intervention: LAVH type IA (vaginal approach to colpotomy)
Number of subjects: 541
Study: 11498314

Group type: EXPERIMENTAL
Intervention: Epidural ketamine 1 mg/kg combined with 50 microg/kg of morphine
Number of subjects: 46

Group type: COMPARATOR
Intervention: Epidural morphine 50 microg/kg
Number of subjects: 46
Study: 9021940

Group type: EXPERIMENTAL
Intervention: 12 g fish oil daily for 1 month (27% EPA, 23% DHA) in group 1 (normal renal function)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 12 g fish oil daily for 1 month (27% EPA, 23% DHA) in group 2 (renal failure)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 12 g fish oil daily for 1 month (27% EPA, 23% DHA) in both groups
Number of subjects: 17
Study: 7889965

Group type: EXPERIMENTAL
Intervention: Single-dose cefuroxime (20 mg/kg intravenously at induction of anaesthesia)
Number of subjects: 844

Group type: COMPARATOR
Intervention: Three-day course of cefuroxime (20 mg/kg intravenously at induction followed by 750 mg t.i.d. for three consecutive days)
Number of subjects: 844
Study: 2851413

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) 7500 AXaU, subcutaneously, starting 2 hours before surgery and continuing for 7 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 100
Study: 29504044

Group type: EXPERIMENTAL
Intervention: Weekly regimen (60,000 IU weekly)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Stoss regimen (600,000 IU on day 1)
Number of subjects: 67
Study: 26382252

Group type: EXPERIMENTAL
Intervention: Pathway-managed group (n=54)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Nonpathway group (n=60)
Number of subjects: 114
Study: 24360025

Group type: EXPERIMENTAL
Intervention: Half volume group (cuff inflated with half the maximum inflation volume)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Resting volume group (cuff inflated with resting volume)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 22427534

Group type: EXPERIMENTAL
Intervention: Addition of all biomarkers (including IL-6, fibrinogen, chemokine ligand 18, surfactant protein D, C-reactive protein, Clara cell secretory protein-16, IL-6 and -8, tumor necrosis factor-α)
Number of subjects: 1843

Group type: EXPERIMENTAL
Intervention: IL-6 alone
Number of subjects: 1843

Group type: COMPARATOR
Intervention: Clinical variables (age, BODE, hospitalization history)
Number of subjects: 1843
Study: 20377320

Group type: EXPERIMENTAL
Intervention: Omalizumab (75-375 mg once or twice a month by subcutaneous injection)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study: 18760150

Group type: EXPERIMENTAL
Intervention: Social skills treatment program (12-week program with weekly 3-hour group sessions and 1-hour individual sessions)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Social activity alone
Number of subjects: 51

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Social skills treatment program
Number of subjects: 51
Study: 21961347

Group type: EXPERIMENTAL
Intervention: Trichloroacetic acid (90%) applied once to the cervix, cul de sacs, and vagina areas
Number of subjects: 28

Group type: COMPARATOR
Intervention: Physiological saline (placebo)
Number of subjects: 28
Study: 14716791

Group type: EXPERIMENTAL
Intervention: Level II axillary node dissection
Number of subjects: 1209

Group type: COMPARATOR
Intervention: Level III axillary node dissection
Number of subjects: 1209
Study: 11205721

Group type: EXPERIMENTAL
Intervention: Specific and individualized treatment for diastolic heart failure (DHF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 8737632

Group type: EXPERIMENTAL
Intervention: 500 mg sustained release film tablets
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 300 mg sustained release film tablets
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 300 mg normally releasing capsules
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Aqueous solution (1 x 1000 mg/d)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 1410128

Group type: EXPERIMENTAL
Intervention: 75 mg velnacrine maleate
Number of subjects: 0
Study: 4073082

Group type: EXPERIMENTAL
Intervention: Ticarcillin plus clavulanic acid
Number of subjects: 25

Group type: COMPARATOR
Intervention: Moxalactam
Number of subjects: 25
Study: 2890542

Group type: EXPERIMENTAL
Intervention: Preparation containing standardized ginseng extract combined with trace elements and multivitamins
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 28884306

Group type: EXPERIMENTAL
Intervention: Probiotic soy milk (200 mL/day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Soy milk (control)
Number of subjects: 48
Study: 28328980

Group type: EXPERIMENTAL
Intervention: Monitoring of cerebral oxygenation by near-infrared spectroscopy with treatment guidelines
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 166
Study: 26144663

Group type: EXPERIMENTAL
Intervention: Kinect-based feedback training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 24
Study: 22638708

Group type: EXPERIMENTAL
Intervention: Intensive nutritional intervention comprising regular dietetic counseling and oral nutritional supplementation for 3 months postoperatively
Number of subjects: 152

Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Intensive nutritional intervention
Number of subjects: 152
Study: 21649534

Group type: EXPERIMENTAL
Intervention: Cilnidipine
Number of subjects: 367

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 367
Study: 18270213

Group type: EXPERIMENTAL
Intervention: CCM treatment for 3 months
Number of subjects: 164

Group type: COMPARATOR
Intervention: Sham treatment for 3 months
Number of subjects: 164
Study: 16815148

Group type: EXPERIMENTAL
Intervention: 50 mg of prednisolone daily for 14 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 14662044

Group type: EXPERIMENTAL
Intervention: Cisplatin plus topotecan (Arm 1, 12 patients)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Paclitaxel 230 mg/m2 plus topotecan (Arm 3, 13 patients)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2 plus topotecan (Arm 4, 32 patients)
Number of subjects: 57
Study: 10455827

Group type: EXPERIMENTAL
Intervention: Dopexamine (1.25 micrograms.kg‐1.min‐1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Prostacyclin (0.5 ng.kg‐1.min‐1)
Number of subjects: 40
Study: 7675940

Group type: EXPERIMENTAL
Intervention: NNC 756 (80 mg)
Number of subjects: 3
Study: 2088189

Group type: EXPERIMENTAL
Intervention: Ofloxacin (400 mg) intravenously every 12 h
Number of subjects: 23

Group type: COMPARATOR
Intervention: Ceftazidime (2 g) intravenously every 8 h
Number of subjects: 23
Study: 230654

Group type: EXPERIMENTAL
Intervention: Arginine vasotocin (AVT) administered subcutaneously at 22.00 and 01.00 h, doses between 2 and 12 micrograms
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Arginine vasotocin (AVT) administered intravenously or perfused to 10 normal adult subjects, doses between 2 micrograms perfused for 4 hours and 12 micrograms perfused for 30 minutes
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo administered subcutaneously
Number of subjects: 14
Study: 31685270

Group type: EXPERIMENTAL
Intervention: Access to an online video during consent process
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional, face-to-face consenting without access to the online video
Number of subjects: 50
Study: 29808340

Group type: EXPERIMENTAL
Intervention: eSNAP intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 26095773

Group type: EXPERIMENTAL
Intervention: EarPopper(®) device
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 29
Study: 24036408

Group type: EXPERIMENTAL
Intervention: PUSH HARD
Number of subjects: 128

Group type: COMPARATOR
Intervention: TWO INCHES
Number of subjects: 128
Study: 22902795

Group type: EXPERIMENTAL
Intervention: Argentine tango dance program (12 months, twice-weekly classes)
Number of subjects: 52

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 52
Study: 20592125

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: individual alpha frequency rTMS
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: continuous theta burst stimulation (cTBS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation (iTBS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: sham rTMS
Number of subjects: 10
Study: 18414100

Group type: EXPERIMENTAL
Intervention: Topical latanoprost applied once daily for 7 days in one-eye trials
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Bilateral treatment with latanoprost
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Correlation of mean diurnal IOP reduction between 2 one-eye trials
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Correlation of fellow eyes in bilateral treatment
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Correlation of baseline IOP at each time point between fellow eyes in one-eye trials and bilateral treatment
Number of subjects: 41
Study: 16625522

Group type: EXPERIMENTAL
Intervention: etifoxine (50 mg tid)
Number of subjects: 191

Group type: COMPARATOR
Intervention: lorazepam (0.5-0.5-1 mg/day)
Number of subjects: 191
Study: 12743558

Group type: EXPERIMENTAL
Intervention: Suplatast tosilate for 6 weeks
Number of subjects: 28
Study: 11783280

Group type: EXPERIMENTAL
Intervention: Jiakang Ning (JKN) capsule
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Jiakang Ning (JKN) with low dose Tapazol
Number of subjects: 85

Group type: COMPARATOR
Intervention: Tapazol control group
Number of subjects: 85
Study: 9101871

Group type: EXPERIMENTAL
Intervention: Parenteral L‐alanyl‐L‐glutamine dipeptide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not receiving parenteral glutamine)
Number of subjects: 0
Study: 1929726

Group type: EXPERIMENTAL
Intervention: Pyrimethamine-sulfadiazine (or sulfisoxazole) and spiramycine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Spiramycine alone
Number of subjects: 52
Study: 6293834

Group type: EXPERIMENTAL
Intervention: Bacmecillinam 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bacmecillinam 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bacmecillinam 400 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pivmecillinam 400 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of Bacmecillinam 400 mg vs Pivmecillinam 400 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bacmecillinam vs Pivmecillinam
Number of subjects: 0
Study: 30859975

Group type: EXPERIMENTAL
Intervention: Aripiprazole Once-Monthly 400mg (AOM 400) administered every 4 weeks for up to 52 weeks
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Aripiprazole Once-Monthly 400mg (AOM 400)
Number of subjects: 464
Study: 30282798

Group type: EXPERIMENTAL
Intervention: Pomalidomide 4 mg (days 1-21), cyclophosphamide 300 mg (days 1, 8, 15, and 22), dexamethasone 40 mg (days 1-4 and days 15-18 of a 28-day cycle) for 4 cycles (PCD)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Pomalidomide-dexamethasone maintenance until disease progression
Number of subjects: 97
Study: 27430319

Group type: EXPERIMENTAL
Intervention: Self-management course (6 weeks duration, includes education, discussions, exchange of experiences, and physical movement exercises)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Drop-in outdoor physical activity (control group)
Number of subjects: 120
Study: 24281275

Group type: EXPERIMENTAL
Intervention: Ropivacaine continuous infusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.9% saline continuous infusion (Control)
Number of subjects: 40
Study: 22706931

Group type: EXPERIMENTAL
Intervention: Structured, web-based handover application
Number of subjects: 241
Study: 20434048

Group type: EXPERIMENTAL
Intervention: Educational video program, one-on-one counseling, and stroke education materials
Number of subjects: 329

Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 329
Study: 18334909

Group type: EXPERIMENTAL
Intervention: Iloperidone 24 mg/d
Number of subjects: 593

Group type: COMPARATOR
Intervention: Ziprasidone 160 mg/d
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Iloperidone 24 mg/d and Ziprasidone 160 mg/d
Number of subjects: 593
Study: 15704615

Group type: EXPERIMENTAL
Intervention: Esomeprazole MUPS 40 mg tablets encapsulated in hard gelatine (Test)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Esomeprazole MUPS 40 mg tablets without hard gelatine capsule (Reference)
Number of subjects: 49
Study: 14614229

Group type: EXPERIMENTAL
Intervention: High-dose GH
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Low-dose GH
Number of subjects: 198
Study: 10417491

Group type: EXPERIMENTAL
Intervention: Aerosol inhalation (2 mg of aerosol)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nebuliser solution only (20 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nebuliser solution plus isotonic saline (20 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nebuliser solution plus saline and procaterol (20 mg)
Number of subjects: 9
Study: 8853774

Group type: EXPERIMENTAL
Intervention: Evening primrose oil (4 g daily for 12 months)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Liquid paraffin capsules (placebo)
Number of subjects: 10
Study: 1346877

Group type: EXPERIMENTAL
Intervention: TRH treatment (4 doses of 400 micrograms 8‐hourly)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: TRH treatment
Number of subjects: 103

Group type: COMPARATOR
Intervention: Betamethasone plus placebo (control)
Number of subjects: 103